Hints and tips:
...Such a transaction would continue the company’s three-year dealmaking spree, which has taken it from a run-of-the-mill generic drugmaker known as Watson Pharmaceuticals, with a market capitalisation of $8bn...
...It bought Watson Pharmaceuticals for $6bn (2012), Ireland-domiciled Warner Chilcott for $9bn (2013) and Forest Laboratories for $25bn (2014)....
...Actavis, the highly acquisitive Dublin-based drugs maker, has agreed to buy New York’s Forest Laboratories for $25bn, its biggest purchase to date....
...He left in 2007 to become chief executive at Watson, the generic drug company that would later acquire Swiss-based Actavis....
...FT EVENING ROUND-UP Actavis buys Forest Laboratories for $25bn: “Actavis, the highly acquisitive Dublin-based drugs maker, has agreed to buy New York’s Forest Laboratories for $25bn, its biggest purchase...
...The FTSE 100 drugmaker’s shares fell as much as 13 per cent after the FDA granted approval for Watson Pharmaceuticals’ Actavis unit to produce a cut-price version of Adderall XR, one of Shire’s top-selling...
International Edition